ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1517	National Cancer Institute	Html	en	Pancreatic Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of pancreatic cancer.	cancer treatment 0.45958 malignant tumor cells 0.419406 body 0.510954 chemotherapy 0.404222 PDQ cancer information 0.497348 clinical trial search 0.455776 pancreas 0.487969 clinical trials 0.753194 nearby lymph nodes 0.471943 cancer information summary 0.460465 clinical trial 0.646358 cancer cells 0.504208 exocrine pancreatic cancer 0.466193 patients 0.395936 treatment clinical trial 0.39568 endocrine pancreatic cancer 0.462275 NCI PDQ cancer 0.417319 Pancreatic Cancer Treatment 0.455234 Treatment Editorial Board 0.392271 small intestine 0.597674 endocrine pancreas cells 0.397632 general cancer information 0.404462 treatment 0.608368 general information 0.413544 new cancer treatments 0.400431	NCI-supported cancer 0.412236 Cancer Information Service 0.405331 specific cancer cells 0.402178 pancreatic cancer 0.933074 pancreatic cancer spreads 0.442487 stage pancreatic cancer 0.467555 treatment clinical trials 0.430898 National Cancer Institute 0.509295 Pancreatic Neuroendocrine Tumors 0.405468 new treatment 0.444026 Radiation therapy 0.523817 Blood. The cancer 0.396713 PDQ summary 0.454317 cancer research process 0.390975 cancer clinical trials 0.486763 tumor 0.448545 high-energy sound waves 0.434518 cancer information summaries 0.402821 comprehensive cancer information 0.402789 internal radiation therapy 0.390099 cancer 0.947965 information 0.519314 standard treatment 0.39251 Recurrent pancreatic cancer 0.47605	CLICK HERE
1545	National Cancer Institute	Html	en	Adult Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma.	red blood cells 0.404993 cancer treatment 0.406441 body 0.406679 PDQ cancer information 0.415705 unfavorable Hodgkin lymphoma 0.403766 Non-Hodgkin Lymphoma Treatment 0.396504 clinical trial search 0.387461 pregnant women 0.365816 favorable Hodgkin lymphoma 0.403909 white blood cells 0.390827 favorable adult Hodgkin 0.379079 unfavorable adult Hodgkin 0.379392 clinical trials 0.634552 lymph nodes 0.463894 cancer information summary 0.39389 clinical trial 0.489293 stem cell transplant 0.415484 recurrent Hodgkin lymphoma 0.402776 adult hodgkin lymphoma 0.802336 patients 0.379207 blood cells 0.446195 weight loss 0.391968 NCI PDQ cancer 0.365284 radiation therapy 0.587067 Nodular sclerosing Hodgkin 0.384149	lymph node groups 0.460532 treatment 0.56475 night sweats 0.39371 Hodgkin Lymphoma Treatment 0.422215 cancer cells 0.401875 cellularity Hodgkin lymphoma 0.419706 swollen lymph nodes 0.429808 treatment clinical trials 0.386111 National Cancer Institute 0.39221 lymph vessels 0.383555 new treatment 0.393163 advanced hodgkin lymphoma 0.435901 Hodgkin lymphomas 0.368401 classical Hodgkin lymphoma 0.419308 bone marrow 0.427904 depletion Hodgkin lymphoma 0.419209 sedimentation rate 0.371778 hodgkin lymphoma 0.94955 cancer clinical trials 0.401646 stage 0.410094 Combination chemotherapy 0.415703 cancer 0.682215 information 0.416232 appropriate cancer treatment 0.37213	CLICK HERE
1558	National Cancer Institute	Html	en	Endometrial Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease.	cancer treatment 0.459672 cancer prevention trials 0.519855 estrogen 0.503683 endometrial cancer prevention 0.633127 protective factors 0.494311 following PDQ summaries 0.487054 PDQ cancer information 0.583616 estrogen receptor modulators 0.479388 oral contraceptives increases 0.455046 uterus 0.455824 clinical trials 0.591442 cancer information summary 0.536389 breast cancer prevention 0.515055 cancer patients 0.456862 cancer risk factor 0.514935 NCI’s PDQ 0.460213 metabolic syndrome 0.469608 Clinical Trials section 0.455747 NCI PDQ cancer 0.511939 endometrial hyperplasia 0.525569 hormone replacement therapy 0.4814 new cases 0.45495 estrogen levels 0.496361 cancer risk factors 0.513284	Cancer prevention 0.648371 cancer protective factor 0.491722 high estrogen levels 0.479463 Cancer Information Service 0.48404 polycystic ovary syndrome 0.484739 prevention clinical trials 0.493334 Prevention Editorial Board 0.485326 treatment clinical trials 0.456257 National Cancer Institute 0.542099 endometrial cancer 0.951484 African American women 0.525683 estrogen therapy 0.459908 higher risk 0.454955 postmenopausal women 0.557323 Cancer Care page 0.476271 PDQ database 0.456704 PDQ summary 0.495085 combination oral contraceptives 0.477913 cancer clinical trials 0.489805 risk factors 0.587492 nonpolyposis colon cancer 0.481746 cancer information summaries 0.48866 comprehensive cancer information 0.488387 risk 0.63452	CLICK HERE
1621	National Cancer Institute	Html	en	Ewing Sarcoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of Ewing sarcoma.	cancer treatment 0.289749 malignant tumor cells 0.276208 soft tissue 0.253817 body 0.332426 type 0.219713 chemotherapy 0.237331 treatments 0.202586 PDQ cancer information 0.292839 clinical trial search 0.246556 extraosseous Ewing sarcoma 0.264218 Ewing sarcoma spreads 0.243807 clinical trials 0.704097 Pediatric Treatment Editorial 0.209616 nearby lymph nodes 0.208892 cancer information summary 0.25517 clinical trial 0.374839 recurrent Ewing sarcoma 0.335434 stage Ewing sarcoma 0.262403 patients 0.209976 Soft Tissue Sarcoma 0.20334 childhood Ewing sarcoma 0.227663 CAR T-cell therapy 0.238653 NCI PDQ cancer 0.207565 Ewing sarcoma family 0.264166 radiation therapy 0.525383	Treatment Editorial Board 0.214583 treatment 0.586815 Ewing sarcoma 0.925686 Ewing sarcoma cells 0.277555 NCI-supported cancer 0.206887 cancer cells 0.457951 metastatic Ewing sarcoma 0.365401 specific cancer cells 0.219988 patient 0.217481 treatment clinical trials 0.236708 National Cancer Institute 0.256904 initial treatment 0.212474 effects cancer treatment 0.221598 new treatment 0.271508 bone 0.246041 metastatic tumor 0.210193 bone marrow 0.235686 Ewing tumor 0.226375 cancer clinical trials 0.279951 stem cell rescue 0.32512 tumor 0.434783 High-dose chemotherapy 0.218893 cancer 0.820936 standard treatment 0.227171	CLICK HERE
1718	National Cancer Institute	Html	en	Pap and HPV Testing	A fact sheet that describes the Pap and HPV tests, possible results from those tests, and the link between HPV and cervical cancer.	Pap test results 0.318639 precancerous cervical lesions 0.292159 squamous cells 0.289348 high-risk HPV 0.671741 First-line HPV testing 0.290741 squamous cell abnormalities 0.296427 primary HPV screening 0.318981 cervical screening 0.408649 glandular cell abnormalities 0.323902 professional cervical cancer 0.287037 cervical cells 0.449089 Pap test 0.978312 HPV testing 0.403472 frequent cervical screening 0.280097 cell abnormalities 0.445026 HPV test 0.442688 negative HPV test 0.307642 cervical cancer screening 0.819575 positive HPV test 0.337496 cervical cancer 0.958343 HPV DNA test 0.30151 Pap cytology test 0.279358 early cervical cancers 0.308324 HPV infections 0.362202	HPV test results 0.327074 abnormal cells 0.314778 abnormal cervical cells 0.343301 precancerous cervical lesion 0.309268 HPV 0.765136 Pap test result 0.433853 different HPV tests 0.296834 cervical cell abnormalities 0.361261 cobas HPV test 0.304363 high-risk HPV types 0.661339 additional high-risk HPV 0.303577 new cervical cancers 0.27692 high-risk HPV type 0.405337 cervical cancer risk 0.324311 HPV cotesting 0.335213 liquid-based Pap cytology 0.286767 future cervical cancer 0.287194 abnormal Pap test 0.300522 HPV infection 0.371378 cells 0.464647 regular cervical screening 0.330087 Routine cervical screening 0.314661 Pap testing 0.293059 cell changes 0.293167	CLICK HERE
1881	National Cancer Institute	Html	es	Tratamiento del sarcoma de Ewing (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del Sarcoma de Ewing.	ewing sarcoma 0.997403 Ewing family 0.318421 Ewing's sarcoma family 0.369762 metastatic ewing sarcoma 0.318472 ewing óseo valor 0.311245 skeletal localized ewing 0.310397 Ewing Grupo 0.309837 non-metastatic ewing 0.310313 Ewing's Sarcoma Studies 0.319442 ewing óseo característica 0.311302 Ewing extraóseo 0.331665 Ewing sarcoma demonstrates 0.319966 Ewing sarcoma with 0.320002 localized ewing tumours 0.310538 localized ewing 0.369471 ewing-like sarcomas 0.313809 Children's Oncology Group 0.332597 ewing sarcoma family 0.424972 Ewing sarcoma patients 0.320654 with ewing 0.35586 Ewing's tumors with 0.311931 Ewing Sarcoma Study 0.321953 with localized ewing 0.320841 primary ewing 0.310256 extraskeletal ewing sarcoma 0.318994	Ewing's Sarcoma Study 0.335323 synovial sarcoma 0.309759 cooperative ewing sarcoma 0.431437 Ewing sarcoma under 0.319395 EWSR1-rearranged Ewing 0.309748 localized ewing tumor 0.320103 ewing extraóseo sarcoma 0.320923 osseous ewing 0.30998 Pediatr Blood Cancer 0.363663 ewing sarcoma defines 0.332159 Intergroup Cooperative Ewing 0.343374 Ewing Sarcoma Studies 0.337882 Genes Chromosomes Cancer 0.320148 ewing's sarcoma 0.626467 Ewing óseo 0.324425 gen ewsr1 0.309831 ewing's tumors 0.326472 secondary ewing 0.310067 Pediatr Hematol Oncol 0.310262 Clin Oncol 0.365031 multifocal ewing sarcoma 0.318953 ewing tumors 0.399514 congenital ewing sarcoma 0.318921 Ewing sarcoma susceptibility 0.318556	CLICK HERE
1935	National Cancer Institute	Html	es	Tratamiento del ependimoma infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del ependimoma infantil.	radiocirugía estereotáctica 0.685192 siguientes procedimientos 0.332065 efectos secundarios meses 0.562136 siguientes áreas 0.378745 huesos dorsales 0.375848 general recidiva 0.34956 efectos tardíos 0.729968 PDQ Efectos tardíos 0.453185 cabo irm 0.352274 líquido cefalorraquídeo 0.982409 punción espinal.Ampliar 0.373407 estudio clínico 0.337757 National Cancer Institute 0.329628	siguientes riesgos 0.321782 Instituto Nacional 0.357335 PDQ Tratamiento 0.392525 determinados cambios 0.326515 gen rela 0.670707 nuevos tipos 0.348217 siguientes factores 0.370167 sistema nervioso central 0.663463 Physician Data Query 0.423559 segura.ampliar craneotomía 0.353248 cuánto tumor 0.478632 siguientes sumarios 0.438618	CLICK HERE
1991	National Cancer Institute	Html	es	Tratamiento del tumor teratoideo/rabdoide atípico del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores teratoideos/rabdoides atípicos del sistema nervioso central infantil	Children’s Cancer Group 0.214389 Brain Tumor Registry 0.228944 Blaney S 0.21303 tumor or malignant 0.212972 highly malignant tumor 0.212766 CNS atypical teratoid 0.213711 nervous system atypical 0.507412 childhood atypical teratoid 0.213555 Instituto Nacional 0.211549 renal rhabdoid tumor 0.229121 teratoid rhabdoid tumours 0.215084 central nervous system 0.954132 rhabdoid tumors 0.527901 atypical teratoid 0.31284 nervous system malignant 0.215465 malignant rhabdoid tumor 0.241559 non-rhabdoid tumor with 0.213028 brain tumor consortium 0.236375 with central nervous 0.221866 Pediatric MATCH 0.208336 system atypical teratoid 0.255953 Children’s Oncology Group 0.209584 Cribriform neuroepithelial tumor 0.211375 with newly 0.207496 teratoid rhabdoid tumors 0.315276	Pediatr Blood Cancer 0.255454 Genes Chromosomes Cancer 0.225267 National Cancer Institute 0.207929 chemotherapy with autologous 0.210383 PDQ Tratamiento 0.209709 Tumor Registry 0.24792 Packer RJ 0.213353 tumor consortium study 0.212376 Pediatr Hematol Oncol 0.251621 Clin Oncol 0.239466 sistema nervioso central 0.330207 patient with 0.207449 brain tumor 0.273366 Pediatric Oncology Group 0.209965 with autologous hematopoietic 0.20843 Germline INI1 mutation 0.207759 with relapsed or 0.208722 término tumor 0.213201 atypical teratoid tumor 0.230394 newly diagnosed 0.211587 Austrian Brain Tumor 0.226397 Oncology Group 0.212124 tumor showing retained 0.210972 pediatric brain tumor 0.239731	CLICK HERE
2071	National Cancer Institute	Html	es	Cirugía para reducir el riesgo de cáncer de seno	Hoja informativa que describe las clases de cirugía para reducir el riesgo de cáncer de seno y las situaciones en las que se puede pensar en esas operaciones.	Surgical Adjuvant Breast 0.526694 PROSE Study Group 0.516256 cáncer invasor 0.567762 brca1 or brca2 0.538495 mastectomía subcutánea 0.530865 Preventing breast 0.511838 Breast Cancer Research 0.523551 risk-reducing surgery 0.507962 with brca1 or 0.509298 brca2 mutation 0.564149 breast screening with 0.51472 Preventive Services Task 0.512338 mastectomy reduces breast 0.516804 alta penetrancia 0.508455 risk after smaller 0.509063 Friebel T 0.508008 PubMed Abstract 0.952028 Clinical Oncology 0.653359 Cancer Journal 0.515034 BRCA2 mutation carriers 0.554396 early breast cancer 0.539203 ¿Cuáles mujeres 0.517292 bilateral mastectomy 0.517477 BRCA2 mutations detected 0.508495 alto riesgo 0.656597	Wickerham DL 0.51571 an overview 0.508367 Costantino JP 0.515178 Cancer Risk Assessment 0.519342 Rebbeck TR 0.508232 developing invasive breast 0.513495 antecedentes familiares 0.554456 riesgo promedio 0.539499 or brca2 mutations 0.536318 breast cancer risk 0.617067 mutation carriers with 0.509322 gen pten 0.510383 breast cancer 0.801718 Breast Cancer Trialists 0.522907 Services Task Force 0.511925 prophylactic mastectomy 0.591377 mujeres portadoras 0.533011 gen brca1 0.561202 contralateral prophylactic mastectomy 0.534028 Cancer Institute 0.511805 Clinical Cancer Research 0.516971 gen brca2 0.561192 gen tp53 0.518098 New England Journal 0.535054	CLICK HERE
3438	National Cancer Institute	Html	es	Exámenes de detección del cáncer de estómago (gástrico) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de estómago (gástrico).	Offerhaus J 0.113586 Cancer Res Clin 0.264444 Cancer high-risk subjects 0.263357 mass screening 0.365942 Leung WK 0.124317 Kobayashi K 0.11932 American Cancer Society 0.823817 detección versus 0.189954 case-control study 0.112022 Tytgat GN 0.125733 CA Cancer 0.258236 Instituto Nacional 0.144846 PDQ Exámenes 0.215492 prospectively followed chinese 0.229607 Estados Unidos 0.202827 Yanaoka K 0.108053 biological agents 0.104643 Morson BC 0.118473 high risk 0.121936 repeated endoscopic screens 0.228776 Lancet Oncol 0.24929 mass screening program 0.337333 mass survey 0.121584 Gastrointestinal Tract 0.130066 Ma JL 0.109737	mass screening techniques 0.150063 Precancerous Lesions 0.123357 Barbara L 0.103989 Cancer Facts 0.263557 Pfeiffer R 0.11257 Costa Rica 0.0971337 detección darán 0.220411 Mathus-Vliegen EM 0.121366 Ubukata T 0.120185 National Cancer Institute 0.793771 Oka M 0.099234 gastric carcinoma 0.217462 Endoscopic screening during 0.138672 serum pepsinogen concentrations 0.241325 New York 0.185957 Clin Oncol 0.132653 Kitahara F 0.112823 Sherlock P 0.239085 X-ray screening seems 0.130764 serum pepsinogen 0.612986 using serum pepsinogen 0.482271 Sato T 0.127922 stomach cancer 0.944477 Wu MS 0.109301	CLICK HERE